FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

Impact · against what's priced in

NovoCure faces a significant setback as the FDA's rejection of Optune Mya for lung cancer brain metastases eliminates a key growth catalyst. The failure to meet key secondary endpoints suggests a lack of clinical benefit that will hinder revenue expansion in this segment for the foreseeable future.

NVCR−0.80: No priced-in read yet

FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

What matters in this story

Insulet: Rivals Are Building Patch Pumps, But Insulet Already Owns The Pharmacy Counter

FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

What matters in this story

Insulet: Rivals Are Building Patch Pumps, But Insulet Already Owns The Pharmacy Counter

How each ticker is affected

Track these names every morning.

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

2 healthcare stocks to turn $10 into $100 by next year

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

What matters in this story

Next reads from the same story arc

Insulet: Rivals Are Building Patch Pumps, But Insulet Already Owns The Pharmacy Counter

FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

What matters in this story

Next reads from the same story arc

Insulet: Rivals Are Building Patch Pumps, But Insulet Already Owns The Pharmacy Counter

How each ticker is affected

Track these names every morning.

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

2 healthcare stocks to turn $10 into $100 by next year

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity